183 related articles for article (PubMed ID: 32658025)
21. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
22. Choice of Induction in the Era of Single-Antigen Bead Testing: An Idiosyncratic Case Report.
Hertig A
Exp Clin Transplant; 2017 Feb; 15(1):114-116. PubMed ID: 28122486
[TBL] [Abstract][Full Text] [Related]
23. Luminex Solid-Phase Crossmatch for De Novo Donor-Specific Antibodies in Living-Donor Related Transplants.
Mehrotra S; Sharma RK; Mayya M; Gupta A; Prasad N; Kaul A; Bhadauria DS
Exp Clin Transplant; 2017 Aug; 15(4):394-399. PubMed ID: 28447925
[TBL] [Abstract][Full Text] [Related]
24. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients.
Everly MJ
Clin Transpl; 2011; ():333-6. PubMed ID: 22755427
[TBL] [Abstract][Full Text] [Related]
25. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
26. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
OʼLeary JG; Samaniego M; Barrio MC; Potena L; Zeevi A; Djamali A; Cozzi E
Transplantation; 2016 Jan; 100(1):39-53. PubMed ID: 26680372
[TBL] [Abstract][Full Text] [Related]
27. Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes.
Jackson KR; Long J; Motter J; Bowring MG; Chen J; Waldram MM; Orandi BJ; Montgomery RA; Stegall MD; Jordan SC; Benedetti E; Dunn TB; Ratner LE; Kapur S; Pelletier RP; Roberts JP; Melcher ML; Singh P; Sudan DL; Posner MP; El-Amm JM; Shapiro R; Cooper M; Verbesey JE; Lipkowitz GS; Rees MA; Marsh CL; Sankari BR; Gerber DA; Wellen J; Bozorgzadeh A; Gaber AO; Heher E; Weng FL; Djamali A; Helderman JH; Concepcion BP; Brayman KL; Oberholzer J; Kozlowski T; Covarrubias K; Desai N; Massie AB; Segev DL; Garonzik-Wang J
Transplantation; 2021 Feb; 105(2):436-442. PubMed ID: 32235255
[TBL] [Abstract][Full Text] [Related]
28. Renal transplantation in 2016: Novel approaches to improve recipient and allograft outcomes.
Malvezzi P; Rostaing L
Nat Rev Nephrol; 2017 Jan; 13(2):73-74. PubMed ID: 28100905
[No Abstract] [Full Text] [Related]
29. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.
DeVos JM; Gaber AO; Knight RJ; Land GA; Suki WN; Gaber LW; Patel SJ
Kidney Int; 2012 Sep; 82(5):598-604. PubMed ID: 22622504
[TBL] [Abstract][Full Text] [Related]
30. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
31. Increasing relevance of donor-specific antibodies in antibody-mediated rejection.
Zito A; Schena A; Grandaliano G; Gesualdo L; Schena FP
J Nephrol; 2013; 26(2):237-42. PubMed ID: 23475460
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
33. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
34. Subclinical Antibody-Mediated Rejection.
Arias M; Serón D; Herrero I; Rush DN; Wiebe C; Nickerson PW; Ussetti P; Rodrigo E; de Cos MA
Transplantation; 2017 Jun; 101(6S Suppl 1):S1-S18. PubMed ID: 28538291
[No Abstract] [Full Text] [Related]
35. Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival.
Everly MJ
Clin Transpl; 2010; ():317-22. PubMed ID: 21696049
[TBL] [Abstract][Full Text] [Related]
36. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.
Cuadrado A; San Segundo D; López-Hoyos M; Crespo J; Fábrega E
World J Gastroenterol; 2015 Oct; 21(39):11016-26. PubMed ID: 26494958
[TBL] [Abstract][Full Text] [Related]
38. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
[TBL] [Abstract][Full Text] [Related]
39. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
Kimball PM; McDougan FA; King A
Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
[TBL] [Abstract][Full Text] [Related]
40. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation.
Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML
Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
